RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill宣布针对埃博拉病毒的新Opaganib中国专利有效期至2035年
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.: 202110229970.9 issued April 29, 2024).
专业生物制药公司RedHill Biopharma Ltd.（纳斯达克股票代码：RDHL）（“RedHill” 或 “公司”）今天宣布发布一份新的中国专利许可通知，该通知涵盖了中国国家知识产权局（CNIPA）作为抑制单链RNA病毒复制（尤其是埃博拉病病毒）疗法的奥帕加尼 [1]，有效期至2035年（中文）专利申请号：202110229970.9（发布于 2024 年 4 月 29 日）。